<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192253</url>
  </required_header>
  <id_info>
    <org_study_id>M19VLC</org_study_id>
    <nct_id>NCT04192253</nct_id>
  </id_info>
  <brief_title>Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)</brief_title>
  <acronym>VULCANize</acronym>
  <official_title>Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes
      invalidating and chronic postoperative morbidity, especially in patients with high stage
      disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour,
      making surgical treatment less extensive thereby diminishing the chance for morbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes
      invalidating and chronic postoperative morbidity, especially in patients with high stage
      disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour,
      making surgical treatment less extensive, thereby diminishing the chance for morbidity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>a prospective, phase ll trial to investigate the response rate of carboplatin and paclitaxel in patients with locally advanced vulvar carcinoma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumour size change by neoadjuvant chemotherapy</measure>
    <time_frame>18 weeks</time_frame>
    <description>tumour size change by neoadjuvant chemotherapy measured by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>avoidance of exenterative or invalidating surgery</measure>
    <time_frame>21 weeks</time_frame>
    <description>number of patients were surgery can be reduced after the neo-adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy related morbidity</measure>
    <time_frame>21 weeks</time_frame>
    <description>Chemotherapy related morbidity measured by reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years after treatment</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Locally Advanced, Squamous Cell Carcinoma of the Vulva</condition>
  <arm_group>
    <arm_group_label>neo-adjuvant Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Carboplatin</intervention_name>
    <description>Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule</description>
    <arm_group_label>neo-adjuvant Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman k 18 years

          -  Signed and written informed consent.

          -  Histologically confirmed squamous cell vulvar carcinoma

          -  World Health Organization performance status of 0-2

          -  Adequate hematological function

          -  Adequate hepatic function

          -  Adequate renal function

          -  Negative pregnancy test for woman of childbearing potential

          -  measurable disease by physical examination

          -  TNM stage T2, any N, MO

        Exclusion Criteria:

          -  Vulvar cancer other than squamous cell carcinoma at biopsy

          -  Previous radiotherapy of the vulva, groins or pelvis

          -  Patients with metastasis limited to the pelvic lymph nodes, who can be primarily
             operated with curative intent

          -  Other diagnosis of malignancy or evidence of other malignancy for 5 years before
             screening for this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>vulva carcinoma</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Amant, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Amant, MD, PhD</last_name>
    <phone>0031205129111</phone>
    <email>f.amant@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NKI-AVL Zijlmans, MD, PhD</last_name>
      <phone>0031205129111</phone>
      <email>h.zijlmans@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Henry Zijlmans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

